Research programme: mitochondrial disorders therapeutics - Mitopharm/NeuroVive

Drug Profile

Research programme: mitochondrial disorders therapeutics - Mitopharm/NeuroVive

Alternative Names: Ciclosporin derivatives - NeuroVive; mPT inhibitors; NICAM; NVP 015; NVP 015 programme; NVP 016; NVP 017; Succinate Prodrugs - NeuroVive/Lund; Succinic acid derivatives - Mitopharm/NeuroVive

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitopharm Limited; NeuroVive Pharmaceutical
  • Class Antineoplastics; Cardiovascular therapies; Ciclosporins; Obesity therapies; Succinates
  • Mechanism of Action Cyclophilin D inhibitors; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mitochondrial disorders
  • No development reported Acute heart failure; Cancer; Obesity; Stroke

Most Recent Events

  • 18 Jun 2018 NVP015 is still in preclinical trials for Mitochondrial disorders in Sweden
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Mitochondrial disorders in Sweden (IV)
  • 04 Nov 2017 No recent reports of development identified for research development in Acute-heart-failure in Sweden (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top